Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion criteria :~* Diagnosis of rheumatoid arthritis ≥3 months duration~* Active disease defined as:~  * at least 8/68 tender joints and 6/66 swollen joints,~ * high sensitivity C-reactive protein (hs-CRP) \>6 mg/l,~ * continuous treatment with MTX for at least 12 weeks prior to baseline visit and on stable dose for at least 6 weeks prior to screening visit.~Part B only:~* Bone erosion based on documented X-ray prior to first study drug intake, or~* Cyclic Citrullinated Peptide (CCP) positive, or~* Rheumatoid Factor (RF) positive.~Exclusion criteria:~* Age \<18 years or \>75 years.~* Treatment with disease-modifying antirheumatic drugs (DMARDs) other than MTX within 4 weeks or 12 weeks prior to screening (depending on DMARDs).~* Past history of non-response to prior Tumor Necrosis Factor (TNF) or biologic treatment.~* Any past or current biologic agents for the treatment of rheumatoid arthritis within 3 months.~* Use of parenteral glucocorticoids or intraarticular glucocorticoids within 4 weeks prior to screening visit.~* Use of oral glucocorticoid greater than 10mg/day or equivalent/day, or a change in dosage within 4 weeks prior to baseline visit.~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Part A: SAR 100 mg qw (Type: EXPERIMENTAL): Sarilumab 100 mg subcutaneous (SC) injection weekly (qw) on top of MTX for 12 weeks.
- Part A: SAR 150 mg qw (Type: EXPERIMENTAL): Sarilumab 150 mg SC injection qw on top of MTX for 12 weeks.
- Part A: SAR 100 mg q2w (Type: EXPERIMENTAL): Sarilumab 100 mg SC injection every other week (q2w) alternating with placebo on top of MTX for 12 weeks.
- Part A: SAR 150 mg q2w (Type: EXPERIMENTAL): Sarilumab 150 mg SC injection q2w alternating with placebo on top of MTX for 12 weeks.
- Part A: SAR 200 mg q2w (Type: EXPERIMENTAL): Sarilumab 200 mg SC injection q2w alternating with placebo on top of MTX for 12 weeks.
- Part A: Placebo qw (Type: PLACEBO_COMPARATOR): Placebo (for sarilumab) qw on top of MTX for 12 weeks.
- Part B Cohort 1: Non-selected Doses (Type: EXPERIMENTAL): Sarilumab 100 mg qw, 150 mg qw or 100 mg q2w SC injections as in Part A on top of MTX up to dose selection. After dose selection, participants were not continued but were allowed to participate in the open-label, long-term, extension study SARIL-RA-EXTEND (LTS11210).
- Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2) (Type: EXPERIMENTAL): Sarilumab 150 mg SC injection q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with open-label highest dose of sarilumab.
- Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2) (Type: EXPERIMENTAL): Sarilumab 200 mg SC injection q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with open-label highest dose of sarilumab.
- Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2) (Type: EXPERIMENTAL): Placebo (for sarilumab) q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with open-label highest dose of sarilumab.

Based on this trial design, predict the completion outcome and termination type (if applicable).